Rapport Therapeutics, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPP research report →
Companywww.rapportrx.com
Rapport Therapeutics, Inc. , operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
- CEO
- Abraham N. Ceesay
- IPO
- 2024
- Employees
- 69
- HQ
- Boston, DE, US
Price Chart
Valuation
- Market Cap
- $1.30B
- P/E
- -15.73
- P/S
- 65.18
- P/B
- 3.58
- EV/EBITDA
- -10.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.54%
- Op Margin
- -611.03%
- Net Margin
- -536.38%
- ROE
- -24.79%
- ROIC
- -25.34%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-111,483,000 · -42.37%
- EPS
- $-2.86 · 24.34%
- Op Income
- $-125,099,000
- FCF YoY
- -31.02%
Performance & Tape
- 52W High
- $42.27
- 52W Low
- $7.73
- 50D MA
- $33.43
- 200D MA
- $27.58
- Beta
- 0.82
- Avg Volume
- 367.90K
Get TickerSpark's AI analysis on RAPP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Third Rock Ventures V, L.P. | sell | 133,618 |
| May 7, 26 | Third Rock Ventures V, L.P. | sell | 271,495 |
| May 8, 26 | Third Rock Ventures V, L.P. | sell | 5,018 |
| Apr 17, 26 | Third Rock Ventures V, L.P. | sell | 426,005 |
| Apr 17, 26 | Yeleswaram Krishnaswamy | sell | 20,225 |
| Apr 10, 26 | Yeleswaram Krishnaswamy | sell | 500 |
| Apr 13, 26 | Yeleswaram Krishnaswamy | sell | 9,165 |
| Apr 14, 26 | Yeleswaram Krishnaswamy | sell | 10,200 |
| Apr 8, 26 | Yeleswaram Krishnaswamy | sell | 360 |
| Mar 30, 26 | Gault Cheryl | sell | 7,161 |
Our RAPP Coverage
We haven't published any research on RAPP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RAPP Report →